If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInsig Ai Plc Regulatory News (INSG)

Share Price Information for Insig Ai Plc (INSG)

Share Price is delayed by 15 minutes
Get Live Data
14.00    0.75 (5.66%)
Bid:
13.50
Ask:
14.50
Spread: 1.00 (7.407%)
Market Cap: £17.86m
INSG Live PriceLast checked at - London Stock Exchange

Intraday Insig Ai Plc Share Chart

New business win

22 Nov 2024 07:00

RNS Number : 2422N
Insig AI Plc
22 November 2024
 

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

22 November 2024

Insig AI plc

 

("Insig AI", the "Company" or the "Group")

 

New business win from existing client following new product offering in AI solutions

 

Insig AI plc (AIM:INSG), the data science and machine learning solutions company serving the asset management industry, is pleased to announce that a London based alternative investment manager with in excess of £100 billion of assets under management has awarded Insig AI with a contract to migrate its data into the cloud, enabling its data to be machine-readable for planned and future AI and machine learning applications and advanced analytics.

The initial contract value is GBP80,000 and is expected to be completed by 31 January 2025.

Richard Bernstein, Insig AI's Chief Executive commented: "In recent months, within the context of growing interest in AI, we have spent time listening to the requirements of asset managers. It is clear that nearly all are willing to embrace AI but lack the in-house expertise to take immediate advantage of what AI has to offer. This is our data science market opportunity. Today's win is the first evidence point of our ability to serve this substantial market where there is a clear business need. I am also pleased to report that this month has seen a substantial increase in new business leads and meetings from prospects keen to hear of our solutions. This augurs well for future new business wins."

 

For further information, please visit www.insg.ai or contact:

 

Insig AI plc

Richard Bernstein, CEO Richard.bernstein@insg.ai

Zeus (Nominated Adviser & Broker)

David Foreman / James Hornigold +44 (0) 203 829 5000

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
CNTPPGMCGUPCPPG
Date   Source Headline
11th Oct 20247:00 amRNSDirector Dealing
2nd Oct 202411:14 amRNSPDMR Dealing
30th Sep 20242:41 pmRNSResult of AGM
6th Sep 20247:00 amRNSDirector/PDMR Dealing
1st Aug 20247:00 amRNSDirector/PDMR Dealing
3rd Jul 20247:00 amRNSConvertible Loan Notes
21st Jun 20242:30 pmRNSHolding(s) in Company
10th Jun 202411:36 amRNSHolding(s) in Company
6th Jun 20247:00 amRNSGrant of options
5th Jun 20247:00 amRNSEquity Subscription and TVR
30th May 20246:28 pmRNSDirector/PDMR Dealing
30th May 20247:02 amRNSShare subscription, director dealing and TVR
30th May 20247:01 amRNSStrategic investment, revenue share and TVR
30th May 20247:00 amRNSBoard changes
2nd May 20247:00 amRNSShare subscription, director dealing and TVR
17th Apr 20247:00 amRNSDirector/PDMR Shareholding
4th Apr 20247:00 amRNSFunding facility, share allotment & PDMR dealing
2nd Apr 20247:00 amRNSTrading update & equity funding facility proposal
28th Dec 20237:00 amRNSInclusion within UN Environment Programme Tool
22nd Dec 20237:00 amRNSDirector/PDMR Shareholding
21st Dec 20237:00 amRNSDirector/PDMR Shareholding
20th Dec 20237:00 amRNSInterim results
28th Nov 20237:00 amRNSAppointment of investor relations adviser and TVR
27th Nov 20237:00 amRNSCorporate development adviser and TVR
15th Nov 20237:00 amRNSDisposal, Loan Conversion, New Project Win & TVR
30th Oct 20237:00 amRNSNew Product Launch
28th Sep 20237:00 amRNSAppointment of Strategic Adviser and TVR
15th Sep 20233:56 pmRNSResult of AGM
15th Sep 20237:00 amRNSAGM Statement
30th Aug 20237:00 amRNSDirector/PDMR Shareholding
24th Aug 20237:00 amRNSDirector/PDMR Shareholding
21st Aug 20237:00 amRNSDirector/PDMR Shareholding
15th Aug 20237:00 amRNSDirector/PDMR Shareholding
14th Aug 20237:00 amRNSFinal Results, Posting of Report and Notice of AGM
1st Aug 20234:42 pmRNSChange of Registered Office
31st Jul 20235:30 pmRNSTotal Voting Rights
4th Jul 20237:00 amRNSRevision of Convertible Loan Facility Agreement
19th May 20237:00 amRNSDirector/PDMR Shareholding
11th May 20237:00 amRNSDirector/PDMR Shareholding
28th Apr 20237:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
25th Apr 20237:00 amRNSDeath of Director
24th Apr 20237:02 amRNSEquity subscription
24th Apr 20237:01 amRNSInsig AI Data & Technology Collaboration with FCA
24th Apr 20237:00 amRNSTrading and operations update
9th Mar 20237:00 amRNSInsig AI showcase Generative AI Product Capability
6th Feb 20237:00 amRNSGenerative AI Product Capability
16th Jan 20237:00 amRNSDirector/PDMR Shareholding
9th Jan 20237:00 amRNSConvertible Loan Facility Drawdown
28th Dec 20227:00 amRNSDirector/PDMR Shareholding
23rd Dec 20227:00 amRNSDirector Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.